MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice

Table 1 Primary pairs for real-time polymerase chain reaction of genes related to hepatic fatty acid metabolism

Gene name	Accession	Forward	Reverse
PPARα	Mm00440939
SREBP-1c	Mm00550338
SCD-1		GTTGGCTCCATCCATTGC	AACCATGGGAAGCCAAGTTT
FAS		AACCTCAGCAACACATCT	CGTTTACAAAGGGCATGCA
MTP	Mm00435015
CPT1		CCCTGGGCATGATTGCAA	AAGAGGACGCCACTCACGAT

PPARα: Peroxisome proliferator-activated receptor α; SREBP-1c: Sterol regulatory element binding transcription factor-1c; SCD-1: Stearoyl-CoA desaturase-1; FAS: Fatty acid synthase; MTP: Microsomal triglyceride transfer protein activity; CPT-1: Carnitine palmitoyltransferase-1.

Table 2 Metabolic laboratory findings from each experimental mice group

Laboratory findings	Lean	ob/ob	ob/ob + MK-0626 (1.5 mg/kg)	ob/ob + MK-0626 (3 mg/kg)
Glucose (mg/dL)	141 ± 43.8	349 ± 15.7	288 ± 17.6a	247 ± 42.5b
Insulin (μU/mL)	1.83 ± 0.61	11.54 ± 0.59	8.42 ± 1.03a	7.83 ± 0.44b
HOMA score	0.63 ± 0.06	9.96 ± 2.32	5.98 ± 0.52a	4.78 ± 0.166b
ALT (U/L)	43.3 ± 10.3	590 ± 109.5	278 ± 70.5a	272.5 ± 131.5a
Adiponectin (μg/mL)	31.15 ± 2.07	34.57 ± 1.25	37.86 ± 3.40	39.90 ± 1.28a

^aP < 0.05,

^bP < 0.01 vs ob/ob mice group. HOMA: Homeostatic model assessment; ALT: Alanine aminotransferase.